We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Ligand Pharmaceuticals Incorporated (LGND) is a leading biotechnology business with stocks listed in the US. It opened the day at US$147.3 after a previous close of US$150.21. During the day the price has varied from a low of USD143.16 to a high of USD153.72. The latest price was USD148.22 (25 minute delay). Ligand Pharmaceuticals Incorporated is listed on the NASDAQ. All prices are listed in US Dollars.
How to buy shares in Ligand Pharmaceuticals Incorporated
- Compare share trading platforms. To buy shares in a US company from Australia you'll need to find a trading platform that offers access to US stock markets. If you're just starting out, look for a platform with low brokerage and foreign exchange fees.
- Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
- Search for Ligand Pharmaceuticals Incorporated. Find the share by name or ticker symbol: LGND. Research its history to confirm it's a solid investment against your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Ligand Pharmaceuticals Incorporated reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
- Decide on how many to buy. At last close price of US$150.21, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of Ligand Pharmaceuticals Incorporated, depending on your broker.
- Check in on your investment. Congratulations, you own a part of Ligand Pharmaceuticals Incorporated. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.
🧪How we chose these brokersFor our Top Picks, we compared our Finder partners using a proprietary algorithm in August 2020. Keep in mind that our top picks may not always be the best for you, and you're encouraged to compare for yourself to find one that works for you. Read our full methodology here to find out more.
What's in this guide?
- Ligand Pharmaceuticals Incorporated key stats
- Compare share trading platforms
- Is Ligand Pharmaceuticals Incorporated stock a buy or sell?
- Ligand Pharmaceuticals Incorporated performance over time
- Can I short Ligand Pharmaceuticals Incorporated shares?
- Are Ligand Pharmaceuticals Incorporated shares over-valued?
- Ligand Pharmaceuticals Incorporated's financials
- How volatile are Ligand Pharmaceuticals Incorporated shares?
- Does Ligand Pharmaceuticals Incorporated pay a dividend?
- Have Ligand Pharmaceuticals Incorporated shares ever split?
- Other common questions
Ligand Pharmaceuticals Incorporated share priceUse our graph to track the performance of LGND stocks over time.
Ligand Pharmaceuticals Incorporated shares at a glance
|52-week range||US$57.24 - US$219.75|
|50-day moving average||US$150.9527|
|200-day moving average||US$109.5817|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||US$28.289|
Compare share trading platforms
Is it a good time to buy Ligand Pharmaceuticals Incorporated stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Ligand Pharmaceuticals Incorporated price performance over time
|1 week (2021-02-19)||3.74%|
|1 month (2021-01-26)||-5.51%|
|3 months (2020-11-25)||69.57%|
|6 months (2020-08-26)||40.67%|
|1 year (2020-02-26)||44.44%|
|2 years (2019-02-26)||19.70%|
|3 years (2018-02-26)||-2.88%|
|5 years (2016-02-26)||52.36%|
Is Ligand Pharmaceuticals Incorporated under- or over-valued?
Valuing Ligand Pharmaceuticals Incorporated stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Ligand Pharmaceuticals Incorporated's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Ligand Pharmaceuticals Incorporated's P/E ratio
Ligand Pharmaceuticals Incorporated's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 4161x. In other words, Ligand Pharmaceuticals Incorporated shares trade at around 4161x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Ligand Pharmaceuticals Incorporated's PEG ratio
Ligand Pharmaceuticals Incorporated's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.6296. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Ligand Pharmaceuticals Incorporated's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Ligand Pharmaceuticals Incorporated's EBITDA
Ligand Pharmaceuticals Incorporated's EBITDA (earnings before interest, taxes, depreciation and amortisation) is US$50.8 million (£0.0 million).
The EBITDA is a measure of a Ligand Pharmaceuticals Incorporated's overall financial performance and is widely used to measure a its profitability.
Ligand Pharmaceuticals Incorporated financials
|Revenue TTM||US$186.4 million|
|Operating margin TTM||16.41%|
|Gross profit TTM||US$96.6 million|
|Return on assets TTM||1.34%|
|Return on equity TTM||-0.4%|
|Market capitalisation||US$2.3 billion|
TTM: trailing 12 months
Shorting Ligand Pharmaceuticals Incorporated shares
There are currently 6.0 million Ligand Pharmaceuticals Incorporated shares held short by investors – that's known as Ligand Pharmaceuticals Incorporated's "short interest". This figure is 40.4% down from 10.0 million last month.
There are a few different ways that this level of interest in shorting Ligand Pharmaceuticals Incorporated shares can be evaluated.
Ligand Pharmaceuticals Incorporated's "short interest ratio" (SIR)
Ligand Pharmaceuticals Incorporated's "short interest ratio" (SIR) is the quantity of Ligand Pharmaceuticals Incorporated shares currently shorted divided by the average quantity of Ligand Pharmaceuticals Incorporated shares traded daily (recently around 871463.94160584). Ligand Pharmaceuticals Incorporated's SIR currently stands at 6.85. In other words for every 100,000 Ligand Pharmaceuticals Incorporated shares traded daily on the market, roughly 6850 shares are currently held short.
However Ligand Pharmaceuticals Incorporated's short interest can also be evaluated against the total number of Ligand Pharmaceuticals Incorporated shares, or, against the total number of tradable Ligand Pharmaceuticals Incorporated shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Ligand Pharmaceuticals Incorporated's short interest could be expressed as 0.37% of the outstanding shares (for every 100,000 Ligand Pharmaceuticals Incorporated shares in existence, roughly 370 shares are currently held short) or 0.6414% of the tradable shares (for every 100,000 tradable Ligand Pharmaceuticals Incorporated shares, roughly 641 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Ligand Pharmaceuticals Incorporated.
Find out more about how you can short Ligand Pharmaceuticals Incorporated stock.
Ligand Pharmaceuticals Incorporated share dividends
We're not expecting Ligand Pharmaceuticals Incorporated to pay a dividend over the next 12 months.
Have Ligand Pharmaceuticals Incorporated's shares ever split?
Ligand Pharmaceuticals Incorporated's shares were split on a 1:6 basis on 19 November 2010. So if you had owned 6 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Ligand Pharmaceuticals Incorporated shares – just the quantity. However, indirectly, the new 500% higher share price could have impacted the market appetite for Ligand Pharmaceuticals Incorporated shares which in turn could have impacted Ligand Pharmaceuticals Incorporated's share price.
Ligand Pharmaceuticals Incorporated share price volatility
Over the last 12 months, Ligand Pharmaceuticals Incorporated's shares have ranged in value from as little as US$57.24 up to US$219.75. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Ligand Pharmaceuticals Incorporated's is 1.2716. This would suggest that Ligand Pharmaceuticals Incorporated's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Ligand Pharmaceuticals Incorporated overview
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing and acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. The company's commercial programs include Promacta, an oral medicine that increases the number of platelets in the blood; Kyprolis and Evomela, which are used to treat multiple myeloma; Baxdela, a captisol-enabled delafloxacin-IV for the treatment of acute bacterial skin and skin structure infections; Nexterone, a captisol-enabled formulation of amiodarone; Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; and Carnexiv, which is indicated as replacement therapy for oral carbamazepine formulations. It also offers bazedoxifene for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; Minnebro for the treatment of hypertension; and Bryxta for non-small cell lung cancer. The company's partners programs, which are in clinical development used for the treatment of cancer, seizure, diabetes, cardiovascular disease, muscle wasting, liver disease, and kidney, and other diseases. It is also developing a small molecule glucagon receptor antagonist for the treatment of Type 2 diabetes mellitus. In addition, the company is involved in the sale of Captisol materials. Ligand Pharmaceuticals Incorporated was founded in 1987 and is headquartered in San Diego, California.
Frequently asked questions
More guides on Finder
How to buy Bumble shares from Australia
Everything we know about the Bumble IPO, plus information on how to buy in.
How to buy MicroStrategy Incorporated shares
Steps to owning and managing MicroStrategy shares.
How to buy shares in Superhero
Everything we know about the Superhero IPO, plus information on how to buy in.
How to buy Kuaishou shares from Australia
Everything we know about the Kuaishou IPO, plus information on how to buy in.
How to invest in the Coinbase (LGND.US) IPO
Everything we know about the Coinbase IPO, plus information on how to buy in.
How to invest in the Databricks (LGND.US) IPO
Everything we know about the Databricks IPO, plus information on how to buy in.
Alternatives to Robinhood in Australia
You can't access Robinhood in Australia, so here are five low-cost alternatives to trade US stocks.
Reddit stocks: 10 stocks on the WallStreetBets radar
Reddit has long been home to a huge retail investing community called WallStreetBets. Find out how to get the latest Reddit-tipped stocks here.
How to buy Koss Corporation shares
Steps to owning and managing Koss shares.
How to buy Express shares
Steps to owning and managing Express shares.
Ask an Expert